<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03780595</url>
  </required_header>
  <id_info>
    <org_study_id>SEDISTRESS</org_study_id>
    <nct_id>NCT03780595</nct_id>
  </id_info>
  <brief_title>Passiflora Extract for Benzodiazepine Withdrawal</brief_title>
  <acronym>SEDISTRESS</acronym>
  <official_title>Efficacy and Safety of the Administration of the Passiflora Extract for Benzodiazepine Withdrawal in Institutionalized Older Adults: Clinical Trial Phase III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nutricion Medica S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nutricion Medica S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this clinical trials is compare the percentage of patient who achieve a reduction
      equal to or greater than 50% in the dose of benzodiazepines at 10 weeks of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the percentage of patients who achieve to reduce the dose of benzodiazepines equal or more than 50% Reduction of the benzodiazepine dose</measure>
    <time_frame>10 weeks of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Benzodiazepine Withdrawal (Disorder)</condition>
  <arm_group>
    <arm_group_label>Passiflora</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Passiflora incarnata</intervention_name>
    <description>Passiflora pills administration up to 6 pills per day</description>
    <arm_group_label>Passiflora</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Control pills administration up to 6 pills per day</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 65 years old

          2. Stable dose of benzodiazepines during last 3 months ( 4mg loracepam per day or
             equivalent)

          3. Capable of giving consent and to answer the questionnaires according to researcher
             criteria

        Exclusion Criteria:

          1. Diagnosis of dementia moderate or severe (Test Minimental ≤ 20).

          2. Acute confusional syndrome at the inclusion

          3. Panic disorder

          4. Obsesive-compulsive disorder

          5. Any type of psycosis or bipolar disorder

          6. Severe Parkison disease diagnosed

          7. Current or past diagnosis of epilepsia

          8. Recent stroke (last month)

          9. Thyroid disorders not controlled or uncompensated

         10. Alteration of deglutition

         11. Previous drugs or alcohol abuse

         12. Hospitalization (more than 24 hours) during the last month

         13. Complex priority treatment (dialisis, chemotherapy...)

         14. Life expectation less than 1 year

         15. Benzodiazepines therapeutic uses not for anxiety or insomnio
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Fernando Agüera</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario 12 de Octubre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>María de Andres</last_name>
    <phone>+34 913 14 92 71</phone>
    <email>mariade.andres@nutricionmedica.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Residencia Albertia Moratalaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Macarena Maroto Algarra, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Residencia Amavir Ciudad Lineal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Figueroa Linki, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Residencia Nogales Imperial</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Mallón Redondo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Residencia Nogales Pontones</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmela Mañas Martínez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Residencia Nogales Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriá León García, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Residencia Albertia Valle de la Oliva</name>
      <address>
        <city>Majadahonda</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liliana González Espinosa, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Residencia Amavir San Agustín</name>
      <address>
        <city>San Agustín del Guadalix</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Luis Cañón, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Residencia Amavir Torrejón</name>
      <address>
        <city>Torrejón De Ardoz</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara González Blazquez, MD</last_name>
    </contact>
    <investigator>
      <last_name>May Ling Carmiña Rodríguez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 18, 2018</study_first_submitted>
  <study_first_submitted_qc>December 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>December 18, 2018</last_update_submitted>
  <last_update_submitted_qc>December 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Benzodiazepine</keyword>
  <keyword>Withdrawal</keyword>
  <keyword>passiflora</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

